Search filters

Filters

Clear All

Phase

  • 10
  • 16
  • 17
  • 11
  • 21
  • 79
  • 37
  • 3
  • 2
  • 74
  • 77
  • 2

Found 79 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 05122: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

All genders
The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC.

NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzxf (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

All genders
This Study tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. We would like to rely on CIRB as the IRB of record for …
 UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation

UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation

All genders
Phase 1
This study is being done because doctors are trying to develop better methods for treating kidney cancer that has spread to other organs in the body. This study will evaluate the initial safety and effectiveness of an investigational drug, avelumab, given in combination with a chemotherapy drug (gemcitabine) that is …

UPCC 02120: PrE0113: A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

All genders
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized …
 EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

18 years - 99 years
All genders
Phase 3
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
 Testing novel drugs or drug combinations to treat breast cancer before surgery

Testing novel drugs or drug combinations to treat breast cancer before surgery

18 years - 99 years
Female
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …
 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …

Cardiovascular function in leukemia patients: an observational prospective study

All genders
In the last decade, both the incidence and the survival of acute leukemia has been increasing. Therefore, detection of associated illnesses is important. We have recently observed that patients with acute leukemia treated with anthracyclines develop a high rate of symptomatic heart failure. To avoid this life-threatening illness, early detection …
 A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

18 years - 90 years
All genders
Phase 2
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
71 - 79 of 79